加载中
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
最新数据
US$14.72
+US$0.14 · +0.96%
盘中时间采用ET。市场数据可能有所延迟。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
盘中时间采用ET。市场数据可能有所延迟。
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.55亿 USD | 6.05亿 USD | 5.09亿 USD | 5.38亿 USD | 5.35亿 USD |
| 销货成本 | 1.67亿 USD | 1.37亿 USD | 1.28亿 USD | 1.15亿 USD | 1.15亿 USD |
| 毛利 | 4.88亿 USD | 4.68亿 USD | 3.81亿 USD | 4.23亿 USD | 4.2亿 USD |
| 研究与开发 | 2.25亿 USD | 2.1亿 USD | 2.23亿 USD | 2.06亿 USD | 2.01亿 USD |
| 销售、一般及管理费用 | 4.18亿 USD | 4.29亿 USD | 3.91亿 USD | 3.06亿 USD | 2.63亿 USD |
| 营业费用 | 6.42亿 USD | 6.39亿 USD | 6.15亿 USD | 5.12亿 USD | 4.64亿 USD |
| 利息收入 | 1811.1万 USD | 5099.7万 USD | 4603.6万 USD | 1579万 USD | 109.7万 USD |
| 利息支出 | — | 1166.3万 USD | 490.6万 USD | 811.3万 USD | 883.9万 USD |
| 折旧和摊销 | 1465万 USD | 1123.5万 USD | 1096.9万 USD | 1062.4万 USD | 1025.1万 USD |
| 营业利润 | −1.54亿 USD | −1.7亿 USD | −2.33亿 USD | −8952.3万 USD | −4433.3万 USD |
| 净利润 | −1.36亿 USD | −1.69亿 USD | −2.07亿 USD | −9253.4万 USD | −5835.1万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$26.00
上涨空间 76.63%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
